MAHEC provides a variety of continuing professional development programs throughout the year to ensure healthcare professionals are up-to-date on best practices for supporting individuals with opioid and substance use disorders. Educational programs support a variety of healthcare professionals and team-based care and are offered on our main campus in Asheville and off site, online, and through Project ECHO®, a live virtual case-based learning platform.
On December 30, 2022, the X-Waiver requirement to prescribe medication for opioid use disorder (MOUD) was eliminated by the federal government under the Mainstreaming Addiction Treatment (MAT) Act.
Though the X-Waiver has been eliminated, there is an additional requirement that controlled medication prescribers have received at least 8 hours of education on treating and managing patients with substance use disorder. MAHEC has developed a training suite in accordance with the recommendations from the DEA and SAMHSA for the Medication Access and Training Expansion (MATE) Act. For more information, including a listing of available modules, please click here
For a guide to curated literature and resources on SUDs prevention and treatment, please click here
MAHEC has partnered with the North Carolina Department of Health and Human Services (NC DHHS) to increase the number of physicians and advanced practice providers who can provide medication-assisted treatment with buprenorphine, also known medication for opioid use disorder (MOUD), a life-saving evidence-based treatment that greatly reduces the risk for relapse and overdose.
Training components and resources include:
You can learn more about this innovative project in the September 2021 - February 2022 Impact Report.
Training is available through August 2022 and is supported by funds from NC DHHS through the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number #NU17CE925024.
MAHEC offers technical assistance for providers and practices that wish to implement office-based opioid treatment with buprenorphine.
For more information about training and technical assistance opportunities, please contact email@example.com.